Atherosclerosis Drugs Market
Atherosclerosis Drugs Market Analysis by Anti-platelet Medications, Cholesterol-lowering Medications, Beta Blockers, ACE Inhibitors, Calcium Channel Blockers, and Diuretics from 2023 to 2033
Analysis of Atherosclerosis Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
- FACT4434MR
- 27 Jan 2023
- Healthcare
- 170 Pages
- 20 Tables
- 99 Figures
Table of Content
- 1. Preface
- 2. Assumptions and Research Methodology
- 3. Executive Summary : Global Market
- 4. Market Overview
- 5. Market Outlook
- 6. Global Market Analysis and Forecast, By Drug Class
- 6.1. Anti-platelet Medications
- 6.2. Cholesterol Lowering Medications
- 6.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
- 6.4. Beta Blockers
- 6.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
- 6.6. Calcium Channel Blockers
- 6.7. Diuretics
- 6.8. Others
- 7. Global Market Analysis and Forecast, By Distribution Channel
- 7.1. Retail Pharmacies
- 7.2. Hospital Pharmacies
- 7.3. Online Pharmacies
- 8. Global Market Analysis and Forecast, By Region
- 8.1. North America
- 8.2. Europe
- 8.3. Asia Pacific
- 8.4. Latin America
- 8.5. Middle East & Africa
- 9. North America Market Analysis and Forecast
- 10. Europe Market Analysis and Forecast
- 11. Asia Pacific Market Analysis and Forecast
- 12. Latin America Market Analysis and Forecast
- 13. Middle East & Africa Market Analysis and Forecast
- 14. Competition Landscape
- 14.1. GlaxoSmithKline Plc
- 14.2. Sanofi
- 14.3. Hoffmann-La Roche Ltd
- 14.4. Bayer AG
- 14.5. Novartis AG
- 14.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
- 14.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 14.8. Mylan N.V.
- 14.9. Amgen Inc.
- 14.10. Pfizer, Inc.
List Of Table
Table 01: Atherosclerosis Pipeline Analysis
Table 02: Atherosclerosis Pipeline Analysis
Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023 to 2033
Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023 to 2033
Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023 to 2033
Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023 to 2033
Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023 to 2033
Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
List Of Figures
Figure 01: Global Market Revenue (US$ Mn) and Distribution (%), by Region, 2023 and 2033
Figure 02: Global Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Market Revenue Share Analysis, by Drug Class, 2023
Figure 04: Market Overview
Figure 05: Global Market Revenue Share, by Drug Class, 2023
Figure 06: Global Market Revenue Share, by Distribution Channel, 2023
Figure 07: Global Market Revenue Share, by Region, 2023
Figure 08: Global Market Revenue (US$ Mn) Forecast, 2023 to 2033
Figure 09: Global Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2023 to 2033
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2023 to 2033
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2023 to 2033
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2023 to 2033
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2023 to 2033
Figure 15: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2023 to 2033
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2023 to 2033
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2023 to 2033
Figure 18: Global Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 19: Global Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 20: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2023 to 2033
Figure 21: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023 to 2033
Figure 22: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023 to 2033
Figure 23: Global Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 24: Global Market Revenue Share Analysis, by Region, 2023 and 2033
Figure 25: Global Market Attractiveness Analysis, by Region, 2023 to 2033
Figure 26: North America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 27: North America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 28: North America Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 29: North America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 30: North America Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 31: North America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 32: North America Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 33: Europe Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 34: Europe Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 35: Europe Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 36: Europe Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 37: Europe Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 38: Europe Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 39: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 40: Asia Pacific Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 41: Asia Pacific Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 43: Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 45: Asia Pacific Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 47: Latin America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 48: Latin America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 50: Latin America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 52: Latin America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 53: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 54: Middle East & Africa Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 55: Middle East & Africa Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 57: Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 59: Middle East & Africa Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 61: Market Position Analysis, 2023, by Tier and Size of the Company
Figure 62: GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 63: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2023
Figure 64: GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 66: Sanofi (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 68: Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2023
Figure 69: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 70: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 71: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2023
Figure 72: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2023
Figure 73: F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 74: Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 75: Bayer AG Breakdown of Net Sales (%), by Region, 2023
Figure 76: Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 77: Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 79: Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2023
Figure 80: Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2023
Figure 81: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 82: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 83: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 84: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2023
Figure 85: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 86: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 87: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2023
Figure 88: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2023
Figure 89: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 90: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 91: Mylan N.V. R&D Expenses (US$ Mn), 2023 to 2023
Figure 92: Mylan N.V. Breakdown of Net Sales, by Region, 2023
Figure 93: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 94: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 95: Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014 to 2023
Figure 96: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 97: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2023
Figure 98: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2023
Figure 99: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Atherosclerosis Drugs Market